BVF Inc. IL Purchases New Holdings in Invivyd, Inc. $IVVD

BVF Inc. IL purchased a new stake in Invivyd, Inc. (NASDAQ:IVVD) in the 4th quarter, HoldingsChannel reports. The institutional investor purchased 19,525,000 shares of the company’s stock, valued at approximately $48,227,000. Invivyd makes up 1.6% of BVF Inc. IL’s investment portfolio, making the stock its 22nd biggest position. BVF Inc. IL owned 0.08% of Invivyd at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Courier Capital LLC bought a new stake in Invivyd during the fourth quarter worth $25,000. Bronte Capital Management Pty Ltd. bought a new stake in Invivyd during the fourth quarter worth $27,000. DRW Securities LLC bought a new stake in Invivyd during the fourth quarter worth $27,000. State of Wyoming bought a new stake in Invivyd during the fourth quarter worth $30,000. Finally, ProShare Advisors LLC bought a new stake in Invivyd during the fourth quarter worth $30,000. 70.36% of the stock is currently owned by institutional investors.

Invivyd Trading Up 4.4%

Shares of Invivyd stock opened at $0.93 on Thursday. The business has a 50-day moving average price of $1.29 and a two-hundred day moving average price of $1.74. Invivyd, Inc. has a 1-year low of $0.48 and a 1-year high of $3.07. The company has a market cap of $274.34 million, a P/E ratio of -3.00 and a beta of 0.63.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%.The business had revenue of $13.74 million for the quarter, compared to analyst estimates of $18.04 million. Equities research analysts forecast that Invivyd, Inc. will post -0.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on IVVD. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a research note on Wednesday, April 29th. BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of Invivyd in a report on Tuesday, June 9th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Invivyd in a report on Monday. Finally, Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.00.

Invivyd Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.